Health Economics

Once these therapies exist, who can pay for them?

Bespoke therapies are likely to be very expensive.  We want to ensure as much equality of access as we can.

We need to learn more about what would be required for genetic medicines to be covered by healthcare providers (private health insurance, the UK NHS, etc.) and whether there are things we can do to help maximise that chance.

In 2025-2027 we will undertake a systematic review of health economic analyses of gene therapies, including submissions to the UK National Institute for Health and Care Excellence (NICE), to assess the state of the field.  

We will also engage with regulators and healthcare payment stakeholders to understand how these decisions are made, and seek to participate in the discussion wherever possible.